SEARCH

SEARCH BY CITATION

References

  • 1
    Begg S, Vos T, Barker B, Stevenson C, Stanley L, Lopez A. The Burden of Disease and Injury in Australia 2003 [report on the Internet]. Canberra ( AUST ) : Australian Institute of Health and Welfare; 2007 [cited 2009 Oct 15]. Available from: http://www.aihw.gov.au/publications/hwe/bodaiia03/bodaiia03.pdf.
  • 2
    Tracey E, Baker D, Chen W, Stavrou E, Bishop J. Cancer in New South Wales: Incidence, Mortality and Prevalence 2005 [report on the Internet]. Sydney ( AUST ) : Cancer Institute NSW; 2007 [cited 2009 Sep 9]. Available from: http://www.cancerinstitute.org.au/cancer_inst/publications/pdfs/cancer-incidence-mortality-prevalence-2005.pdf.
  • 3
    Degenhardt L, Hall W, Lynskey M, Warner-Smith M. Illicit drug use. In: EzzatiM, LopezAD, RodgersA, MurrayR, editors. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva ( CHE ) : World Health Organization; 2004. p. 110976.
  • 4
    Darke S, Degenhardt L, Mattick RP. Mortality Amongst Illicit Drug Users. Cambridge ( UK ) : Cambridge University Press; 2006.
  • 5
    Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect. 2006;82 Suppl III:5663.
  • 6
    Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F. Mortality of intravenous drug users in Rome: A cohort study. Am J Public Health. 1991;81(10):130710.
  • 7
    Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction. 2008;103(6):90518.
  • 8
    Watson B, Conigrave KM, Wallace C, Whitfield JB, Wurst F, Haber PS. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. Drug Alcohol Rev. 2007;26(3):2319.
  • 9
    Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol. 2005;20(7):10826.
  • 10
    Hser YI, McCarthy WJ, Anglin MD. Tobacco use as a distal predictor of mortality among long-term narcotics addicts. Prev Med. 1994;23(1):619.
  • 11
    Burns L, Mattick RP, Cooke M. Use of record linkage to examine alcohol use in pregnancy. Alcohol Clin Exp Res. 2006;30(4):6428.
  • 12
    Sullivan MA, Covey LS. Current perspectives on smoking cessation among substance abusers. Curr Psychiatry Rep. 2002;4(5):38896.
  • 13
    Hall S, Holman CD, Sheiner H, Hendrie D. The influence of socio-economic and locational disadvantage on survival after a diagnosis of lung or breast cancer in Western Australia. J Health Serv Res Policy. 2004;9 Suppl 2:1016.
  • 14
    Bentley R, Kavanagh AM, Subramanian SV, Turrell G. Area disadvantage, individual socio-economic position, and premature cancer mortality in Australia 1998 to 2000: A multilevel analysis. Cancer Causes Control. 2008;19(2):18393.
  • 15
    World Health Organization. Manual of the International Statistical Classification of Diseases. Injuries and Causes of Death. 9th rev. Geneva ( CHE ) : WHO; 1977.
  • 16
    World Health Organization. Manual of the International Statistical Classification of Diseases. Injuries and Causes of Death. 10th rev. Geneva ( CHE ) : WHO; 1993.
  • 17
    Australian Bureau of Statistics. 2005 Causes of Death, Australia [report on the Internet]. Canberra ( AUST ) : ABS; 2007 [cited 2010 Mar 16]. Available from: http://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/3FFF8096D9500CA9CA25729D001C0B05/$File/33030_2005.pdf.
  • 18
    Australian Bureau of Statistics. 3321.0.55.001 – Drug Induced Deaths, Australia, 1991–2001. Explanatory Notes [report on the Internet]. Canberra ( AUST ) : ABS; 2003 [cited 2010 Mar 16]. Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3321.0.55.001Explanatory%20Notes11991-2001?OpenDocument.
  • 19
    Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, et al. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention. Addiction. 2009;104(8):136372.
  • 20
    Black E, Roxburgh A, Degenhardt L, Bruno R, Campbell G, de Graaff B, et al. Australian Drug Trends 2007: Findings from the Illicit Drug Reporting System (IDRS). Sydney ( AUST ) : National Drug and Alcohol Research Centre, University of New South Wales; 2008.
  • 21
    National Centre in HIV Epidemiology and Clinical Research. Australian NSP Survey National Data Report 2003–2007. Sydney ( AUST ) : National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; 2008.
  • 22
    European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2008: The State of the Drugs Problem in Europe [report on the Internet]. Luxembourg ( LUX ) : Office for Official Publications of the European Communities; 2008 [cited 2010 Mar 16]. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_64227_EN_EMCDDA_AR08_en.pdf.
  • 23
    Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, Vlahov D, et al. Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS. 1994;8(3):34550.
  • 24
    Bjornaas MA, Bekken AS, Ojlert A, Haldorsen T, Jacobsen D, Rostrup M, et al. A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo. BMC Psychiatry. 2008;8:8.
  • 25
    Ferreros I, Lumbreras B, Hurtado I, Pérez-Hoyos S, Hernández-Aguado I. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users. Addiction. 2008;103(4):6519.
  • 26
    Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract. 2009;15(3):22734.
  • 27
    Maxwell JC, Pullum TW, Tannert K. Deaths of clients in methadone treatment in Texas: 1994–2002. Drug Alcohol Depend. 2005;78(1):7381.
  • 28
    Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: A brief review of recent epidemiological evidence. Lung Cancer. 2004;45 Suppl 2:39.
  • 29
    International Agency for Research on Cancer. Alcohol Drinking. Vol 44 [monograph on the Internet]. Lyon ( FRA ) : IARC Press; 1988 [cited 2010 Feb]. Available from: http://monographs.iarc.fr/ENG/Monographs/vol44/volume44.pdf.
  • 30
    Grulich AE, De Visser RO, Smith AMA, Rissel CE, Richters J. Injecting and sexual risk behaviour in a representative sample of adults. Aust N Z J Public Health. 2003;27(2):24250.
  • 31
    Sikstrom B, Hellberg D, Nilsson S, Mardh PA. Smoking, alcohol, sexual behaviour and drug use in women with cervical human palpillomavirus infection. Arch Gynecol Obstet. 1995;256(3):1317.
  • 32
    Plitt SS, Sherman SG, Viscidi RP, Strathdee SA, Fuller CM, Taha TE. Human papillomavirus seroprevalence among young male and female drug users. Sex Transm Dis. 2007;34(9):67680.
  • 33
    International Agency for Research on Cancer. Human Papillomaviruses. Vol 90 [monograph on the Internet]. Lyon ( FRA ) : IARC Press; 2005 [cited 2010 Feb]. Available from: http://monographs.iarc.fr/ENG/Monographs/vol90/mono90.pdf.
  • 34
    Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204.
  • 35
    Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103(9):148492.
  • 36
    Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):187986.
  • 37
    Burns L, Mattick RP, Cooke M. The use of record linkage to examine illicit drug use in pregnancy. Addiction. 2006;101(6):87382.
  • 38
    Gachupin-Garcia A, Selwyn PA, Salisbury Budner N. Population-based study of malignancies and HIV infection among injecting drug users in a New York City methadone treatment program, 1985–1991. AIDS. 1992;6(8):8438.
  • 39
    Chau S, Chin M, Chang J, Luecha A, Cheng E, Schlesinger J, et al. Cancer risk behaviors and screening rates among homeless adults in Los Angeles County. Cancer Epidemiol Biomarkers Prev. 2002;11(5):4318.
  • 40
    Hall SM, Prochaska JJ. Treatment of smokers with co-occurring disorders: Emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol. 2009:40931.
  • 41
    Reid MS, Fallon B, Sonne S, Flammino F, Nunes EV, Jiang H, et al. Smoking cessation treatment in community-based substance abuse rehabilitation programs. J Subst Abuse Treat. 2008;35(1):6877.
  • 42
    Pettersson F, Bjorkholm E, Naslund I. Evaluation of screening for cervical cancer in Sweden: Trends in incidence and mortality 1958–1980. Int J Epidemiol. 1985;14(4):5217.
  • 43
    Kariminia A, Butler T, Corben S, Kaldor J, Levy M, Law M. Mortality among prisoners: How accurate is the Australian Nationa Death Index? Aust N Z J Public Health. 2005;29(6):5725.